Please select the option that best describes you:
Are you using genomic classifiers to diagnose UIP when imaging is indeterminate or suggestive of an alternate diagnosis?
Answer from: at Community Practice
Antifibrotics are indicated for the treatment of IPF, scleroderma-ILD, and progressive pulmonary fibrosis, not specifically for "UIP," which can manifest in any of the three.
When a patient presents with an indeterminate pattern on CT without suggestive features of connective tissue disease on hist...
Sign in or Register to read more
Answer from: at Academic Institution
The guidelines neither endorse nor discourage the use of genomic classifiers in diagnosing IPF or other ILDs, leaving considerable variability in clinical practice, often relying on expert opinion. Similar to Dr. @Southern, we primarily employ genomic classifiers in patients with indeterminate HRCT ...
Comments
at Lake Pointe Medical Center
I learned something new.
I learned something new.
Answer from: at Academic Institution
Yes, we utilize the genomic classifier in cases where the pattern is indeterminate for UIP, and occasionally when distinguishing between NSIP and UIP, or in tandem with BAL and TBBx when HP is under consideration. However, this is only done when the pre-test probability for UIP is significant. Given...
Answer from: at Community Practice
I think I've done 5-10 genomic classifiers, predominantly in patients with indeterminate UIP patterns and the occasional probable patient in which I'm pretty hedgy. I will say that, anecdotally, my patients regularly return positive. I don't think this is a problem of the test; rather, it likely ref...